Edelman Joseph's Form 4 filing
Cerevel Therapeutics Holdings, Inc.CERE · filed Aug 18, 2022
- Accession no.
- 0001062993-22-018390
- Filed
- Aug 18, 2022, 5:10 PM ET
- Trade date
- Aug 16, 2022
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 1 non-derivative transaction and 1 derivative transaction. Open-market purchases total $49.9M. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Edelman JosephCIK 0001164426 | Director |
| Perceptive Advisors LLCCIK 0001224962 | Director |
| Perceptive Life Sciences Master Fund LtdCIK 0001249675 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Aug 16, 2022 | Common Stock | PPurchaseAcquired | +1,425,000 | $35.00 | +$49,875,000 | 6,511,727 | Indirect |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Aug 16, 2022 | Common Stock | PPurchaseAcquired | +2,156,102 | $100,000,000.00 | – | – | Indirect | Price outlier |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.